These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 23042423)

  • 1. Reconstructing analgesic trials: reasons for following the lead of oncologists.
    Davis MP; Mitchell G
    Curr Opin Support Palliat Care; 2012 Dec; 6(4):490-3. PubMed ID: 23042423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic-pharmacodynamic relationships for analgesics.
    Suri A; Estes KS; Geisslinger G; Derendorf H
    Int J Clin Pharmacol Ther; 1997 Aug; 35(8):307-23. PubMed ID: 9266286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group.
    Gray R; Manola J; Saxman S; Wright J; Dutcher J; Atkins M; Carducci M; See W; Sweeney C; Liu G; Stein M; Dreicer R; Wilding G; DiPaola RS
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):1966-9. PubMed ID: 16609005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accelerating the development of improved analgesic treatments: the ACTION public-private partnership.
    Dworkin RH; Turk DC
    Pain Med; 2011 Jul; 12 Suppl 3():S109-17. PubMed ID: 21752182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.
    El-Maraghi RH; Eisenhauer EA
    J Clin Oncol; 2008 Mar; 26(8):1346-54. PubMed ID: 18285606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early phase drug development for treatment of chronic pain--options for clinical trial and program design.
    Kalliomäki J; Miller F; Kågedal M; Karlsten R
    Contemp Clin Trials; 2012 Jul; 33(4):689-99. PubMed ID: 22401888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seamless phase II/III designs.
    Stallard N; Todd S
    Stat Methods Med Res; 2011 Dec; 20(6):623-34. PubMed ID: 20724313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic-pharmacodynamic modeling in acute and chronic pain: an overview of the recent literature.
    Martini C; Olofsen E; Yassen A; Aarts L; Dahan A
    Expert Rev Clin Pharmacol; 2011 Nov; 4(6):719-28. PubMed ID: 22111858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints.
    Jenkins M; Stone A; Jennison C
    Pharm Stat; 2011; 10(4):347-56. PubMed ID: 22328327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How large should a phase II trial of a new drug be?
    Simon R
    Cancer Treat Rep; 1987 Nov; 71(11):1079-85. PubMed ID: 3315196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].
    Ludwig WD
    Z Evid Fortbild Qual Gesundhwes; 2012; 106(1):11-22. PubMed ID: 22325103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What can chronic arthritis pain teach about developing new analgesic drugs?
    Witter J; Dionne RA
    Arthritis Res Ther; 2004; 6(6):279-81. PubMed ID: 15535840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel designs and end points for phase II clinical trials.
    Adjei AA; Christian M; Ivy P
    Clin Cancer Res; 2009 Mar; 15(6):1866-72. PubMed ID: 19276272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A flexible multi-stage design for phase II oncology trials.
    Tan MT; Xiong X
    Pharm Stat; 2011; 10(4):369-73. PubMed ID: 22328328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving the design of phase II trials of cytostatic anticancer agents.
    Stone A; Wheeler C; Barge A
    Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing the early phase development of new analgesics by human pain biomarkers.
    Arendt-Nielsen L; Hoeck HC
    Expert Rev Neurother; 2011 Nov; 11(11):1631-51. PubMed ID: 22014141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adaptive designs at European Organisation for Research and Treatment of Cancer (EORTC) with a focus on adaptive sample size re-estimation based on interim-effect size.
    Mauer M; Collette L; Bogaerts J;
    Eur J Cancer; 2012 Jun; 48(9):1386-91. PubMed ID: 22281098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacology and rationale of analgesic combinations.
    Desmeules J; Rollason V; Piguet V; Dayer P
    Eur J Anaesthesiol Suppl; 2003; 28():7-11. PubMed ID: 12785456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II clinical trials in oncology: are we hitting the target?
    Ang MK; Tan SB; Lim WT
    Expert Rev Anticancer Ther; 2010 Mar; 10(3):427-38. PubMed ID: 20214523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opioid and adjuvant analgesics: compared and contrasted.
    Khan MI; Walsh D; Brito-Dellan N
    Am J Hosp Palliat Care; 2011 Aug; 28(5):378-83. PubMed ID: 21622486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.